New drug approvals in 1999.
Wynn
R L
RL
Department of Oral-Craniofacial Biological Sciences, Dental School, University of Maryland at Baltimore, USA.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D017277:Drug Approval; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D006801:Humans; D007783:Lactones / Q000627:therapeutic use; D013450:Sulfones; D014481:United States; D014486:United States Food and Drug Administration; D014769:Virginiamycin / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib; D014769:Virginiamycin; C062940:quinupristin-dalfopristin